These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33161658)

  • 1. [The analysis of detection of rare diseases not included into listings of orphan diseases with preferential medication support].
    Komarov IA; Krasilnikova EI; Zhulev IA; Zinchenko RF
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Sep; 28(5):893-902. PubMed ID: 33161658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The rare diseases and orphan medications: Placement in health care of the Russian Federation].
    Komarov IA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):16-19. PubMed ID: 36801869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The orphan preparations: international approaches and national regulation].
    Foteeva AV; Rostova NB; Isupova AD; Gerbergagen ES
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2021 Nov; 29(6):1490-1497. PubMed ID: 34882322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The characteristics of restrictive listings of medications: the position of orphan medical preparations].
    Komarov IA
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2022 Dec; 30(6):1328-1330. PubMed ID: 36541317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The legal regulation of life cycle of orphan pharmaceuticals].
    Gildeyeva GN; Kartavtsova TV
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The pharmacy tourism. Part I. The analysis of state of medicinal support of patients with rare diseases].
    Ananchenkova PI; Tonkonog VV; Timchenko TN
    Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Jan; 31(1):33-43. PubMed ID: 36801872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Orphan diseases and orphan medicines: a Belgian and European study].
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
    Wonder M; Chin G
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-approval Studies for Rare Disease Treatments and Orphan Drugs.
    Maier WC; Christensen RA; Anderson P
    Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The first results of the analysis of the activity of the cancer service of the North-Western Federal district of the Russian Federation, conducted on the basis of the created population cancer register of the Federal district.].
    Merabishvili VM; Belyaev AM
    Adv Gerontol; 2020; 33(2):228-239. PubMed ID: 32593236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Orphan drugs: availability, reliability and reimbursement].
    Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
    Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues surrounding orphan disease and orphan drug policies in Europe.
    Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
    Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic considerations in the provision of treatments for rare diseases.
    McCabe C; Edlin R; Round J
    Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe.
    Luisetti M; Balfour-Lynn IM; Johnson SR; Miravitlles M; Strange C; Trapnell BC; van Bronswijk H; Vogelmeier C
    Respir Med; 2012 Jun; 106(6):759-68. PubMed ID: 22414566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparing for the Future of Rare Diseases.
    Groft SC; Posada de la Paz M
    Adv Exp Med Biol; 2017; 1031():641-648. PubMed ID: 29214596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of the use of treatments not included in the reimbursement classes in the care of rare patients: a real world study.].
    Mazzucato M; Minichiello C; Visonà Dalla Pozza L; Vianello A; Toto E; De Lorenzi M; Scroccaro G; Facchin P
    Recenti Prog Med; 2022; 113(7):440-450. PubMed ID: 35852080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.